2 completed. 2 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 2 | Completed 2 |
Follow MD1003: new trials by email Literature Review of MD1003 trials Research Report on MD1003
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| SERENDEM : MD1003 in Patients Suffering From Demyelinating Neuropathies, an Open Label Pilot Study MD1003 - Chronic Inflammatory Demyelinating Polyneuropathy, Peripheral Neuropathy | Phase 2 | Completed | MedDay Pharmaceuticals SA | 15 | 2016-12-05 | 2020-11-02 |
| Effect of MD1003 in Amyotrophic Lateral Sclerosis MD1003, Placebo oral capsule - ALS, Amyotrophic Lateral Sclerosis | Phase 2 | Completed | MedDay Pharmaceuticals SA | 30 | 2016-06-29 | 2019-06-04 |
Amyotrophic Lateral Sclerosis (1) · Charcot-Marie-Tooth Disease (1) · Motor Neuron Disease (1) · Peripheral Nervous System Diseases (1) · Polyradiculoneuropathy, Chronic Inflammatory Demyelinating (1)
France (2)